{"id":42730,"date":"2016-06-24T13:05:49","date_gmt":"2016-06-24T17:35:49","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=42730"},"modified":"2016-06-24T19:56:02","modified_gmt":"2016-06-25T00:26:02","slug":"oral-tranexamic-acid-ta-in-the-treatment-of-melasma-a-retrospective-analysis","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/42730","title":{"rendered":"Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis"},"content":{"rendered":"<p><!--more--><\/p>\n<div>Lee HC<sup>1<\/sup>, Thng TG<sup>2<\/sup>, Goh CL<sup>2<\/sup>.<\/div>\n<div>\n<h3>Abstract<\/h3>\n<div>\n<h4>BACKGROUND:<\/h4>\n<p>Melasma is a common pigmentary disorder among Asians and treatment is challenging. Oral tranexamic acid (TA) has emerged as a potential treatment for refractory melasma. Large-scale studies on its use, outcomes, and safety are limited.<\/p>\n<h4>OBJECTIVE:<\/h4>\n<p>We sought to evaluate treatment outcomes and adverse effects of oral TA in melasma in an Asian population.<\/p>\n<h4>METHODS:<\/h4>\n<p>We conducted a retrospective analysis of patients who received oral TA for melasma in a tertiary dermatologic center from January 2010 to June 2014.<\/p>\n<h4>RESULTS:<\/h4>\n<p>In all, 561 patients (91.4% female, 8.6% male) were enrolled. Median duration of treatment was 4\u00a0months. The\u00a0majority (503 [89.7%]) improved, 56 (10.0%) had no improvement, and 2 (0.4%) worsened. Patients without family history of melasma had better response rates than those with family history (90.6% vs 60.0%, P\u00a0=\u00a0.01). Of the 503 who improved, response was seen <span class=\"aBn\" tabindex=\"0\" data-term=\"goog_721582415\"><span class=\"aQJ\">within 2\u00a0months<\/span><\/span> of TA initiation, with a relapse rate of 27.2%. Adverse events occurred in 40 (7.1%). Most were transient, but 1 developed deep vein thrombosis requiring prompt discontinuation. She was later given the diagnosis of familial protein S deficiency.<\/p>\n<h4>LIMITATIONS:<\/h4>\n<p>This was a retrospective study.<\/p>\n<h4>CONCLUSION:<\/h4>\n<p>Oral TA may be an effective adjunct for refractory melasma. Careful screening for personal and familial risk factors for thromboembolism should be done before initiation.<\/p>\n<\/div>\n<\/div>\n<div>\n<h4>KEYWORDS:<\/h4>\n<p>angiogenesis; chloasma; facial pigmentation; melanogenesis; melasma; tranexamic acid<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-42730","post","type-post","status-publish","format-standard","","category-articulos-cientificos"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/42730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=42730"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/42730\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=42730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=42730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=42730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}